Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical feature of the study subjects

From: Establishment of clinical diagnosis model of Graves’ disease and Hashimoto’s thyroiditis

Items GD
n = 119
HT
n = 78
P value
Gender (M/F) 41/78 9/69 < 0.001
Age 38.73 ± 13.73 37.65 ± 10.79 0.560
FT3 20.99 ± 14.36 14.31 ± 10.91 < 0.001
FT4 52.31 ± 30.26 40.27 ± 23.88 0.003
TSH 0.01 ± 0.03 0.02 ± 0.42 0.038
TGAb 362.52 ± 587.11 550.96 ± 757.63 0.050
TPOAb 226.37 ± 209.04 274.39 ± 477.62 0.335
TRAb 9.67 ± 10.68 5.75 ± 9.6 0.010
2-h RAIU 31.15 ± 16.75 22.79 ± 17.12 < 0.001
6-h RAIU 47.92 ± 20.79 32.82 ± 23.88 < 0.001
24-h RAIU 57.74 ± 20.44 38.49 ± 26.57 < 0.001
RAIU-AUC 1109.22 ± 433.67 753.13 ± 527.79 < 0.001
  1. M: male; F: female; GD: Graves’ disease; HT: Hashimoto’s thyroiditis; FT3: free T3; FT4: free T4; TSH: thyroid stimulating hormone; TGAb: thyroglobulin antibody; TPOAb: thyroid peroxidase antibodies; TRAb: thyrotropin receptor antibody; RAIU: radioactive iodine uptake; AUC: area under the curve